Form 4: Outlook Therapeutics Director Gerd Auffarth Receives Stock Options

Director Gerd Auffarth received multiple stock option grants from Outlook Therapeutics, vesting over the next year and expiring in 2034.

Summary

• Gerd Auffarth, a director of Outlook Therapeutics, received stock options on October 1, 2024, and October 3, 2024.
• The options have an exercise price of $5.22 and $5.25.
• 56,636 options were granted as an annual stock option grant, vesting fully on October 1, 2025.
• 29,493 options were granted under the 2024 Equity Incentive Plan, vesting fully on October 1, 2025.
• 12,082 options were granted in lieu of $55,000 in cash fees, vesting in four equal quarterly installments, fully vested by September 30, 2025.
• All options are subject to acceleration upon a Change in Control, provided the Reporting Person provides continuous service to the Issuer immediately prior to such Change in Control.
• The options expire on October 1, 2034, and October 3, 2034.

Sentiment

Score: 6

Explanation: The document reflects a routine director compensation update, which is neutral to slightly positive as it incentivizes management.

Positives

• The granting of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry to attract and retain talent and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedules and terms are generally consistent with industry practices to incentivize long-term performance and retention.
• Comparable companies like Ocular Therapeutix and Aldeyra Therapeutics also utilize stock options as part of their director compensation.

Stakeholder Impact

• Shareholders may view the option grants positively as they align director interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates